Known targets — ChEMBL curated mechanism
AURKAAURKBCSF1RFGFR3FLT3KDRKIT
The experimentally established mechanism targets of Enmd-2076. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AURKA known ✓ | O14965 | 16/20 | 1.00 |
| ▸ | AURKB known ✓ | Q96GD4 | 7/20 | 1.00 |
| ▸ | CSF1R known ✓ | P07333 | 2/20 | 1.00 |
| ▸ | KIT known ✓ | P10721 | 2/20 | 1.00 |
| ▸ | KDR known ✓ | P35968 | 2/20 | 1.00 |
| ▸ | FLT3 known ✓ | P36888 | 2/20 | 1.00 |
| ▸ | FGFR3 known ✓ | P22607 | 2/20 | 1.00 |
| ▸ | NTRK1 | P04629 | 3/20 | 1.00 |
| ▸ | PLK4 | O00444 | 2/20 | 1.00 |
| ▸ | ABL1 | P00519 | 2/20 | 1.00 |
| ▸ | LCK | P06239 | 2/20 | 1.00 |
| ▸ | RET | P07949 | 2/20 | 1.00 |
| ▸ | FGFR1 | P11362 | 2/20 | 1.00 |
| ▸ | SRC | P12931 | 2/20 | 1.00 |
| ▸ | PDGFRA | P16234 | 2/20 | 1.00 |
| ▸ | TYK2 | P29597 | 2/20 | 1.00 |
| ▸ | PTK2 | Q05397 | 2/20 | 1.00 |
| ▸ | MAP4K5 | Q9Y4K4 | 2/20 | 1.00 |
| ▸ | CHEK1 | O14757 | 1/20 | 1.00 |
| ▸ | PDPK1 | O15530 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Enmd-2076 SCHEMBL10122873 | 1.00 | AURKA (1.00) | AURKAAURKBNTRK1PLK4ABL1 | |
| Enmd-2076 SCHEMBL15668060 | 1.00 | AURKA (1.00) | AURKAAURKBNTRK1PLK4ABL1 | |
| Enmd-2076 SCHEMBL10122872 | 1.00 | AURKA (1.00) | AURKAAURKBNTRK1PLK4ABL1 | |
| SCHEMBL10122902 | 0.94 | AURKA (0.89) | AURKAAURKBNTRK1PLK4ABL1 | |
| Enmd-2076 SCHEMBL29379147 | 0.92 | AURKA (1.00) | AURKAAURKBNTRK1PLK4ABL1 | |
| Enmd-2076 SCHEMBL15239834 | 0.92 | AURKA (1.00) | AURKAAURKBNTRK1PLK4ABL1 | |
| Enmd-2076 SCHEMBL29381911 | 0.92 | AURKA (1.00) | AURKAAURKBNTRK1PLK4ABL1 | |
| Enmd-2076 SCHEMBL29389572 | 0.92 | AURKA (1.00) | AURKAAURKBNTRK1PLK4ABL1 | |
| SCHEMBL2499073 | 0.92 | AURKA (0.85) | AURKAAURKBNTRK1PLK4ABL1 | |
| SCHEMBL2499079 | 0.92 | AURKA (0.85) | AURKAAURKBNTRK1PLK4ABL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1595 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-122057044-A | Nanometer liposome delivery system for targeting PLK1/Aurora kinase and application thereof in oral squamous cell carcinoma treatment | 徐州医科大学 | 2026-05-19 | — | — | CN | claimed |
| US-20260097028-A1 | Methods of Treating Myeloproliferative Neoplasms | KARTOS THERAPEUTICS INC (US) | 2026-04-09 | — | — | US | claimed |
| US-12594421-B2 | Compositions and methods for increasing cancer cell sensitivity to alternating electric fields | NOVOCURE GMBH (CH) | 2026-04-07 | — | — | US | claimed |
| US-12522873-B2 | ALK and NTRK1 fusion molecules and uses thereof | FOUNDATION MEDICINE, INC. (US) | 2026-01-13 | — | — | US | claimed |
| EP-3957329-B1 | COMPOSITION COMPRISING THE COMBINATION OF SOTAGLIFLOZIN AS THE SODIUM/GLUCOSE CO-TRANSPORTER 1 INHIBITOR (SGLT1) AND A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR 2 INHIBITOR (VEGFR2) FOR USE IN TREATING CANCER | NEWISH TECH BEIJING CO LTD (CN) | 2025-11-19 | — | — | EP | claimed |
| WO-2025216949-A1 | METHODS FOR TREATING A TUMOR WITH ANTI-CDH6 ANTIBODY DRUG CONJUGATES | ONCUSP THERAPEUTICS, INC. (US) | 2025-10-16 | — | — | WO | claimed |
| EP-4629993-A1 | METHODS OF TREATING MYELOPROLIFERATIVE NEOPLASMS | Kartos Therapeutics (US) | 2025-10-15 | — | — | EP | claimed |
| US-20250312349-A1 | COMPOSITION AND METHODS OF TREATING INTRACELLULAR PATHOGEN INFECTION | UNIV HOSPITALS CLEVELAND MEDICAL CENTER (US) | 2025-10-09 | — | — | US | claimed |
| EP-3250192-B1 | COMPOSITIONS AND METHODS OF USING TYROSINE KINASE INHIBITORS | UNIV YALE (US) | 2025-10-08 | — | — | EP | claimed |
| US-12350261-B2 | Methods and devices for the treatment of ocular diseases in human subjects | CLEARSIDE BIOMEDICAL, INC. (US) | 2025-07-08 | — | — | US | claimed |
| US-11331272-B2 | Hyperstabilized liposomes increase targeting of mitotic cells | TEMASEK LIFE SCIENCES LABORATORY LIMITED (SG) | 2022-05-17 | — | — | US | claimed |
| EP-3980563-A2 | NTRK FUSION MOLECULES AND USES THEREOF | Foundation Medicine, Inc. (US) | 2022-04-13 | — | — | EP | claimed |
| US-20220096818-A1 | Compositions And Methods For Increasing Cancer Cell Sensitivity To Alternating Electric Fields | BIOPHARMA CREDIT PLC (GB) | 2022-03-31 | — | — | US | claimed |
| EP-3964217-A1 | USE OF COMPOUND OR PHARMACEUTICALLY ACCEPTABLE SALT, DIMER OR TRIMER THEREOF IN PREPARATION OF DRUG FOR TREATING CANCER | Newish Technology (Beijing) Co., Ltd. (CN) | 2022-03-09 | — | — | EP | claimed |
| EP-3957310-A1 | COMPOSITION AND USE THEREOF IN PREPARATION OF MEDICATION FOR TREATING CANCER | Newish Technology (Beijing) Co., Ltd. (CN) | 2022-02-23 | — | — | EP | claimed |
| EP-3957329-A1 | COMPOSITION FOR TREATING CANCER, APPLICATION THEREOF, AND DRUG | Newish Technology (Beijing) Co., Ltd. (CN) | 2022-02-23 | — | — | EP | claimed |
| CN-114028568-A | Method for preventing or treating side effects of tumor therapy | 上海岸阔医药科技有限公司 | 2022-02-11 | — | — | CN | claimed |
| WO-2022029628-A1 | COMPOSITIONS AND METHODS FOR INCREASING CANCER CELL SENSITIVITY TO ALTERNATING ELECTRIC FIELDS | NOVOCURE GMBH (CH) | 2022-02-10 | — | — | WO | claimed |
| US-20220040324-A1 | COMBINATION OF ANTIBODY-DRUG CONJUGATE AND KINASE INHIBITOR | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2022-02-10 | — | — | US | claimed |
| CN-113975264-A | Method for preventing or treating side effects of tumor therapy | 上海岸阔医药科技有限公司 | 2022-01-28 | — | — | CN | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260097028-A1 | Methods of Treating Myeloproliferative Neoplasms | JAK2, TP53, CDKN1A | AURKA 740/4885AURKB 524/4885CSF1R 1465/4885 |
| US-12594421-B2 | Compositions and methods for increasing cancer cell sensitivity to alternating electric fields | PTK2, GSK3B, MTOR | AURKA 173/4885AURKB 140/4885CSF1R 1626/4885 |
| US-20220040324-A1 | COMBINATION OF ANTIBODY-DRUG CONJUGATE AND KINASE INHIBITOR | WEE1, ERBB3, ERBB2 | AURKA 16/4885AURKB 21/4885CSF1R 135/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.